

LUMAVITA

Lumavita AG

Novel Anti-infectives for Women's Health

Safe Harbor

LUMAVITA

This communication contains certain forward-looking statements, including, without limitation, statements containing the words "believes", "anticipates", "expects", "supposes", "considers" and words of similar import. Such forward-looking statements involve known and unknown risks, and certainties and other factors, which may cause the actual results, financial condition, performance, or achievements of Lumavita AG, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the early stage of the Company's development and uncertainties related to its technology, the uncertainty of pre-clinical and clinical trials of potential products, limited supplies, future capital needs and the uncertainty of additional funding, the need for regulatory approval of the Company's operations and potential products, dependence on licenses, patents and proprietary technology, competition from other biotechnology, chemical and pharmaceutical companies, attraction and retention of technologically skilled employees, lack of sales and marketing structure and dependence on partners for commercialization of potential products, limited manufacturing capabilities, management's discretion as to use of proceeds, risks of product liability and limitations on insurance, uncertainties relating to health care reform, adverse changes in governmental rules and fiscal policies and other factors referenced in this communication. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. The Company and the authors of this communication disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Overview

LUMAVITA

- Privately-owned, specialty biopharma company
- Global development and commercialisation of novel anti-infectives for women's health
- Proprietary product portfolio: low dose FemiFect® for treatment of vaginitis approved in Switzerland August 2009 – launch imminent
- Addressing large and under-served markets – vaginitis alone worth \$2.4 billion
- Leading the field in R&D of a new class of anti-viral compounds – PC-PLC inhibitors
- CHF 24mio Series A closed in June 2009
- Based in Basel, Switzerland


3

Combating infections for women's health

LUMAVITA

- Global markets with high unmet medical needs
- No treatments for vaginitis that address all three sources of infection: bacteria, fungi, protozoa
- Result is many patients fail to respond adequately to treatment; recurrence is common
- PC-PLC inhibitors have the potential to treat HPV – a major cause of cervical cancer and a \$1.1 billion market
- Focus on gynaecologists - a well defined market
 - gives Lumavita the opportunity to build a unique specialty biopharma company with a low risk profile

4




FemiFect® – a treatment for vaginitis

LUMAVTA

- Vaginitis is either a bacterial, fungal, protozoan or mixed infection and includes:
 - Bacterial vaginosis
 - Candidiasis
 - Trichomoniasis vaginalis
- Core need is for a broad spectrum treatment covering all three major causes
- Inadequate treatments and resulting frequent infection (40% recurrence rates¹) result in increased risk of miscarriage and infertility
 - Additional sources of differentiation for FemiFect®: recurrence rates; resistant pathogens; safety in pregnancy
- 110 million prescriptions written per year worldwide (IMS)
- FemiFect® is a broad spectrum macrolide antibiotic (pentamycin)
- Clinical trials to date in 1,300 patients show FemiFect® to be effective against all three major causes of infection

¹ Sobel JD., Am J Obstet Gynecol., 1985;152 (7 Pt 2):324-335

6



FemiFect® – low dose **LUMAVTA**

- Approval received from SwissMedic late August 2009
- Launch in Switzerland imminent
- Thereafter, RoW submissions and launches anticipated
- Swiss CPP required for submission and registration in 116 countries
- Distribution network established to bring low-dose FemiFect® to Latin America, Asia & CIS – potentially 30% of global market

8

FemiFect® – dose-optimised version in development

LUMAVITA

- Superior three-day dosing schedule
- Phase IIb program underway to optimise dose for key markets of North America and EU - 70% of global market
- Phase IIb study (n=372) anticipated completion Q1 2010
- Phase III program anticipated to run Q2 2010 to Q4 2011


9

PC-PLC inhibition: lead compound LMV-601

LUMAVITA

- First in a new class of anti-viral compounds with a novel mechanism of action
 - Phosphatidylcholine-specific phospholipase C inhibitors
- Suitable for topical applications
- Proof-of-concept achieved in humans for herpes genitalis
- In late-stage pre-clinical development for the treatment of HPV
- The World Health Organisation estimates that world prevalence of HPV infection is between 9-13% of adults

10



LMV-601: a potential treatment for HPV **LUMAVTA**

- **HPV is an underserved market for those having contracted the infection**
 - Vaccines can not treat or cure infected patients
- **Number of infected patients is enormous**
 - In US, between 24 million and 40 million are infected
 - Additional 5.5 million people acquire a genital form of HPV infection in every year
 - HPV is the most commonly diagnosed sexually transmitted disease in US and UK
 - WHO estimates that the world prevalence of HPV infection is between 9% and 13%
- **HPV treatment market potential > \$1.1 billion with very limited drugs available**
 - Many patients are treated by surgical methods (e.g., cryotherapy)
 - Aldara (imiquimod, Graceway, ex-3M): \$260 million in 2005
 - Polyphenon E (Medigene): approved in US
 - Podophylin (chemotherapy), topical interferons and Vistide (cidofovir)
- **HPV is treated by gynaecologists**
 - Synergistic overlap in target audience with FemiFect®

12

Company strategy	LUMAVITA
<ul style="list-style-type: none"> ▪ Build a specialty biopharmaceutical company focused on well defined gynaecology target audience ▪ Launch low-dose FemiFect® through establishment of a network of distributor partnerships in Switzerland, Latin America, Asia, CIS ▪ Progress clinical development for dose-optimised FemiFect® and LMV-601 ▪ Maintain all options open for Commercialisation of dose-optimised FemiFect® in all geographies ▪ Operate a lean business model through the outsourcing of lab, clinical trial and manufacturing requirements = low infrastructure costs 	
13	

Scientific Advisors	LUMAVITA
<ul style="list-style-type: none"> ▪ Prof. Jack Sobel, MD <ul style="list-style-type: none"> ▪ Wayne State University, Detroit, USA ▪ Leading world authority on vaginitis ▪ Prof. Jonathan Zenilman, MD <ul style="list-style-type: none"> ▪ Johns Hopkins School of Medicine, Baltimore, USA ▪ Leading authority on infectious Diseases ▪ Prof. Paul Nyirjesy, MD <ul style="list-style-type: none"> ▪ Drexel University, Philadelphia, USA ▪ Leader in Infectious Diseases in Gynaecology ▪ Prof. Eberhard Amtmann PhD <ul style="list-style-type: none"> ▪ DKFZ in Heidelberg, Germany ▪ Discovery of LMV601, leader in phospholipase research field ▪ Prof. Rainer E. Weissenbacher M.D. , Ph.D <ul style="list-style-type: none"> ▪ University-hospital Grosshadern, München Germany ▪ Leader in infectious diseases in Gynecology 	
14	

Anticipated 18-month Milestones

LUMAVTA

- Approval of low-dose FemiFect® in Switzerland 2009
- Swiss & RoW launches of low-dose FemiFect® starting 2009
- Completion of Phase IIb FemiFect® dose-optimised trial Q1 2010
- LMV-601 entry-into-man Q1 2010
- Industry figure to join Board